Market Place
Sourcing Support
Kyverna Therapeutics Business Update & Reports Q3 Results
13 Nov 2024 //
PR NEWSWIRE
Kyverna Highlights KYV-101 Potential for Neuroinflammation at ECTRIMS 2024
18 Sep 2024 //
PR NEWSWIRE
Kyverna Therapeutics Announces Leadership Update
16 Sep 2024 //
PR NEWSWIRE
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
21 Aug 2024 //
BIOSPACE
Céline Dion`s Diagnosis, Stiff-Person Syndrome Researchers Advance Towards Cure
15 Aug 2024 //
FIERCE BIOTECH
Kyverna Therapeutics Reports Q2 2024 Results And Business Update
12 Aug 2024 //
PR NEWSWIRE
Kyverna`s KYV-101 Gets FDA IND Clearance For Stiff-Person Syndrome Trial
20 Jun 2024 //
PR NEWSWIRE
Kyverna`s CAR-T relapse in lupus dents autoimmune hopes
17 Jun 2024 //
FIERCE BIOTECH
Kyverna To Attend AAN With KYV-101 Neuro Autoimmune Data
11 Apr 2024 //
PR NEWSWIRE
Kyverna Provides Business Update and Reports FY23 Financial Results
26 Mar 2024 //
PR NEWSWIRE
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101
07 Mar 2024 //
PR NEWSWIRE
Kyverna Therapeutics Announces Closing of Initial Public Offering
12 Feb 2024 //
PR NEWSWIRE
Kyverna CEO: `We`re in the next phase of medicine`
09 Feb 2024 //
FIERCE BIOTECH
Kyverna overshoots raised IPO expectations with $319M offering
08 Feb 2024 //
FIERCE BIOTECH
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
07 Feb 2024 //
PR NEWSWIRE
Kyverna raises IPO expectations to almost $300M
06 Feb 2024 //
FIERCE BIOTECH
Kyverna seeks $182M IPO as biotech runs multiple autoimmune CAR-T trials
01 Feb 2024 //
ENDPTS
Kyverna eyes $180M IPO haul to fund autoimmune CAR-T trials
01 Feb 2024 //
FIERCE BIOTECH
Kyverna says CAR-T manufacturing times can be cut through blood collection efficiencies
25 Jan 2024 //
ENDPTS
Kyverna accelerates into another FDA fast track
19 Jan 2024 //
FIERCE BIOTECH
CAR-T developer Kyverna is latest clue biotech IPOs are back
17 Jan 2024 //
FIERCE BIOTECH
Kyverna Therapeutics files for IPO as autoimmune CAR-T space heats up
16 Jan 2024 //
ENDPTS
Autoimmune CAR-T biotech Kyverna is considering an IPO next month
12 Jan 2024 //
ENDPTS
Kyverna`s KYV-101 Receives Clearance for Treatment of Multiple Sclerosis
03 Jan 2024 //
PR NEWSWIRE
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101
13 Dec 2023 //
PR NEWSWIRE
Kyverna Therapeutics Announces Publication in The Lancet Neurology
15 Nov 2023 //
PR NEWSWIRE
Kyverna Therapeutics Announces FDA Clearance of Phase 2 IND for KYV-101
13 Nov 2023 //
PR NEWSWIRE
Kyverna Therapeutics Hosts a CAR T-Cell Therapy Symposium in Berlin
10 Nov 2023 //
PR NEWSWIRE
Kyverna Announces Achievement of Phase 1 Trial of CD19 CAR T-Cell Therapy
13 Sep 2023 //
PR NEWSWIRE
GordonMD® Invests in Clinical Stage Cell Therapy Company Kyverna
15 Aug 2023 //
BUSINESSWIRE
Kyverna adds $60M to the bank as it prepares to showcase early CAR-T data
02 Aug 2023 //
ENDPTS
FDA grants clearance to commence Kyverna’s lupus nephritis therapy trial
14 Nov 2022 //
CLINICALTRIALSARENA
Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101
12 Nov 2022 //
PRNEWSWIRE
Kyverna Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis
18 Oct 2022 //
PRNEWSWIRE
Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer
13 Oct 2022 //
PRNEWSWIRE
Kyverna Therapeutics Names Peter Maag as CEO
13 Oct 2022 //
PRNEWSWIRE
Kyverna Therapeutics Appoints Tom Van Blarcom as SVP and Head of Research
26 Aug 2022 //
CONTRACTPHARMA
Kyverna Therapeutics Names T.V. Blarcom, as Senior VP, Head of Research
23 Aug 2022 //
PRNEWSWIRE
Kyverna locks in Gilead, Intellia for $85M financing
26 Jan 2022 //
FIERCEBIOTECH
Kyverna Therapeutics Closes $85M Series B Financing led by Northpond Ventures
26 Jan 2022 //
PRNEWSWIRE
Intellia bags option on Kyverna’s autoimmune CAR-T prospect
06 Jan 2022 //
BIOSPACE
Kyverna Bags Excl. WW Licenses With NIH for Anti-CD19 CAR T Cellular Therapies
03 Jan 2022 //
PRNEWSWIRE
Autoimmune biotech Kyverna snags longtime Amgen exec as CMO
14 Apr 2021 //
FIERCE BIOTECH
